Skip to content

    Concord Biotech Limited

    CONCORDBIOGood
    Healthcare·12 Nov 2024
    Management Summary

    Concord Biotech delivered a robust Q2 FY25, characterized by strong top-line and bottom-line growth of 18%. The quarter was marked by a significant shift in revenue mix, with the formulation business scaling rapidly to 26% of sales. While this shift caused some gross margin compression due to the lower-margin nature of formulations compared to niche APIs, management remains confident in achieving double-digit API growth for the full year and sustaining its 25% long-term growth trajectory.

    Highlights

    7

    • Revenue for Q2 FY25 stood at ₹310 crores, representing an 18% YoY growth.

    • Profit After Tax (PAT) reached ₹99 crores, growing 18% YoY with a steady 32% margin.

    • Formulation segment witnessed explosive growth of 125% YoY, contributing 26% of total revenue.

    • EBITDA increased by 15% YoY to ₹137 crores, with margins at 44%.

    • API business reported revenue of ₹230 crores, showing muted external growth due to higher captive consumption for formulations.

    • Company remains debt-free with cash and bank balances of ₹284 crores as of September 30, 2024.

    • Management maintained long-term CAGR guidance of 25% despite shift in product mix.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹310 Cr+18%YoY
    2. 02EBITDA₹137 Cr+15%YoY
    3. 03EBITDA Margin44%
    4. 04PAT₹99 Cr+18%YoY
    5. 05PAT Margin32%0%YoY

    Segment breakdown

    • API₹230 Cr74.2%
    • Formulations₹80 Cr25.8%
    Donut· Share of Revenue

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Long-term CAGR
    25%
    		High
    Capacity
    Injectable Facility Commercialization
    February 2025
    		Medium
    Other
    API to Formulation Revenue Mix
    80:20
    		High
    Other
    New Product Launches
    2-3 products
    		High

    Risks & concerns

    4
    RiskSeverity

    Gross Margin Compression

    The shift in revenue mix toward formulations (26% vs 15% YoY) is diluting gross margins as formulations have lower profitability than niche APIs. — Both acknowledged

    medium

    Regulatory Inspection Uncertainty

    Unit 1 is still awaiting a US FDA inspection; while the track record is good, the timing remains unscheduled. — Analyst acknowledged

    medium

    Working Capital in Institutional Sales

    Government institutional orders for formulations have longer receivable cycles compared to corporate hospitals and trade business. — Management

    low

    Areas of Evasion(1)

    • Specific margin profiles for API vs. Formulations were described as 'varied' without giving exact percentage points.

    Q&A highlights

    3

    “intercompany sales from API to formulations at the end gets recorded in formulations only. And hence, API had shown that muted growth... if we include this API sales made to formulation... the API growth would be around 9% to 10%.”

    Explains the optical slowdown in the core API business as being driven by internal consumption for the high-growth formulation segment.

    asked by Alankar Garude, Kotak Institutional Equities

    2 min read5 chapters

    Detailed Narrative

    01

    Formulation Segment Drives Growth Amidst API Mix Shift

    The formulation business was the standout performer in Q2 FY25, growing 125% YoY to reach ₹80 crores. This segment now accounts for 26% of total revenue, up from 15% in the previous year. Management clarified that the seemingly muted 3% growth in external API sales for H1 is due to higher captive consumption; if interunit sales were included, API growth would be approximately 9-10%. The company expects the API segment to return to double-digit growth for the full fiscal year as new orders from LATAM and other regions materialize.

    02

    Strategic Moat in Fermentation-Based APIs

    Concord Biotech continues to leverage its position as a global leader in fermentation-based APIs, particularly in immunosuppressants. With a total fermentation capacity of 1,250 cubic meters, the company faces limited competition, primarily from European and Southeast Asian players rather than Chinese manufacturers. This niche positioning has protected the company from the pricing volatility seen in the broader API sector, with management reporting stable pricing across its core portfolio.

    03

    Injectable Facility Timeline and Future Pipeline

    The commercialization of the new injectable facility has been rescheduled to February 2025 from the initial September/October 2024 target. This delay is attributed to extra caution during media fill studies and water system qualifications. Despite the delay, the R&D pipeline remains robust with 8-10 new products targeting a $1 billion API market size. The company plans to launch 2-3 products annually, focusing on high-value segments like oncology and anti-infectives.

    04

    Capacity Utilization and Operational Efficiency

    Operational data revealed varying utilization levels across sites: Unit 1 is at 79%, Unit 2 at 50%, and the newer Unit 3 (Limbasi) at 38%. The lower utilization at Limbasi is expected to improve as anti-infective and antifungal products transition from qualification samples to commercial supply. Management noted that as these facilities scale, operating leverage should help offset the margin pressure currently seen from the higher mix of formulation sales.

    05

    Financial Strength and Capital Allocation

    Concord remains a zero-debt company with a strong liquidity position of ₹284 crores in cash and investments. While current capex is focused on maintenance, management indicated an openness to inorganic growth opportunities, specifically targeting 'adjacencies to fermentation.' The company's 32% PAT margin and 44% EBITDA margin remain among the highest in the sector, supported by backward integration into critical starting materials.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.